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In order to define additional diagnostic criteria for 
the early diagnosis of Sezary's syndrome (SS), periph-
eral blood lymphocytes of 32 patients with erythro-
derma, including 8 patients with SS, 4 patients with 
erythrodermic mycosis fungoides, 14 patients with an 
erythroderma on the basis of atopic or chronic derma-
titis, and 6 patients with erythrodermic psoriasis, were 
investigated by computer-assisted morphometry. The 
degree of nuclear indentation, expressed as the nuclear 
contour index (NCI), was measured on electron micro-
graphs. The mean NCI and the percentages of cerebri-
form mononuclear cells (CMC), defined by a NCI:;;. 6.5, 
were calculated. In addition, the percentages of lympho-
cytes, T and B cells, and the distribution ofT-cell sub-
populations as defined by Fc-receptors (TIL, T'Y) and 
monoclonal antibodies (0KT3, OKT4, OKT8, HLA-DR) 
were determined. 
Statistical analysis showed as most discriminating pa-
rameters for the differentiation between SS and benign 
forms of erythroderma: high percentages of lympho-
cytes (50% or more), an expanded OKT3+, OKT4+ pop-
ulation with an OKT4/0KT8 ratio > 10, a mean NCI 
value :;;. 5.5, the presence of more than 20% CMC, as 
well as the presence of cells with a NCI:;;. 11.5. The total 
leukocyte and lymphocyte counts, as well as the per-
centages of B, T, TI-L, and T'Y cells had limited value for 
the early diagnosis of SS. 
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Abbreviations: 
CMC: ce rebriform mononuclear ce lls 
CTCL: cutaneous T -celllymphoma 
FCS: fetal ca lf se rum 
MF: mycosis fungoides 
NC I: nuclear contour index 
PBS: phosphate-buffered saline 
SS: Sezary's syndrome 
Sezary's syndrome (SS), first described in 1938 [1] is clini-
cally characterized by a pruritic exfoliative or infiltrated ery-
throderma, lymphadenopathy, and the presence of atypical 
mononuclear cells (Sezary cells) in the peripheral blood [2,3]. 
At present most investigators regard SS as a neoplastic disease 
and part of the spectrum of cutaneous T-cell lymphomas 
(CTCL) [4,5]. In the early stage of the disease the clinical and 
histologic features are not diagnostic and differentiation from 
erythroderma on the basis of chronic dermatitis, atopic der-
matitis, or psoriasis is difficult. In these patients with generally 
normal leukocyte counts the diagnosis rests mainly upon dem-
onstration of Sezary cells in the peripheral blood. However, 
objective criteria for recognition of Sezary cells by light mi-
croscopy are lacking [6]. Moreover, ultrastructural studies have 
demonstrated t he presence of cerebriform mononuclear cells 
(CMC), similar to those in SS, in the peripheral blood of 
patients with generalized benign dermatoses [7] . 
In order to define additional diagnostic criteria for the early 
diagnosis of SS, we have performed computer-assisted mor-
phometry and marker studies of peripheral blood lymphocytes 
of 32 patients with erythroderma, including 8 patients with SS, 
4 with erythrodermic mycosis fungoides (MF) , and 20 patients 
with various benign forms of erythroderma. 
MATERIALS AND METHODS 
Patients 
Heparinized venous blood was obtained from 32 patients with ery-
throderma including 8 patients with SS, 4 with erythrodermic MF, 14 
with chronic dermatitis, and 6 with psoriasis. The peripheral blood 
from 10 healthy donors served as controls. 
The diagnosis of SS was based on clinical and histologic criteria: 
eryth roderma, lymphadenopathy, a nd the presence of hyperconvoluted 
lymphoid cells, compatible with Sezary cells, in the peripheral blood. 
The patients with erythrodermic MF had shown the classica l Alibert-
Bazin type of MF"for 3 months (see Table I, no. 9) to more than 4 
years (nos. 10- 12) before the erythroderma developed. At the t ime of 
study all patients had enlarged inguinal lymph nodes. Histologic ex-
amination showed dermatopathic lymphadenopathy in 2 patients (nos. 
9 and 10), early involvement according to the criteria of Scheffer et al 
[8] in 1 patient (no. 11), and diffuse MF involvement in another patient 
(no. 12) with progressive leukemic disease, which proved to be fatal 
within 5 months. The clinical data of the patients with SS and MF at 
the time of study are shown in Table I. 
Nov. 1983 
From the 14 patients with erythroderma on t he basis of chronic 
dermatitis, 7 patients (nos. 13-19) had atopic erythrode rma. Histolog-
ically, most of t hese cases were characte rized by a bandlike mononu-
clear infiltrate in the upper dermis, containing varying numbers of 
C MC. The peripheral blood smea rs of some of t hese patients demon -
strated low numbers of atypical lymphoid cells. Howeve r, hyperconvo-
luted Sezary cells could not be identified. During the follow-up period 
which ranged from 12- 48 months (24 months or more in 10 patients) 
none of these 14 patients developed SS or MF. At t he time of study 
t he patients with erythroderma on t he basis of chronic dermatitis or 
psoriasis received no other than topical t reatment with eit her emol-
lients or steroids. 
L y mphocyte Isolation 
Heparinized peripheral blood was di luted with an equal volume of 
p hosphate-buffered saline (PBS, pH 7.2). To remove monocytes, car-
bonyl iron particles were added and the mixture was incubated at 37 ' C 
for 30 min wi t h occasiona l shaking. The monocyte-depleted mononu -
c lear cells were then isolated by Ficoll -Isopaque (P = 1.077 g/ cm3 ) 
density-gradient centrifugation fo r 20 min at 1200 g. The cells present 
in the interphase were washed 3 t imes wi th PBS supplemented wi th 
10% heat-inactivated fetal ca lf serum (FCS) and subsequent ly stored 
in liquid ni t rogen in minimal essential medium supplemented with 
10% FCS and 10% dimethyl sulfoxide un t il used for membrane marker 
o r ult rastructural studies. 
Membrane Marker Stu.dies 
T, TJ.L, and T 'Y lymphocytes were detected by means of a mixed 
rosette assay using neuraminidase-treated sheep erythrocytes and fluo-
r escein-labeled ox erythrocytes coated with either rabbit lgM or igG 
a ntibodies. The specificity, sensit ivity, and experimental conditions 
h ave been described in deta il elsewhere [9]. B lymphocytes were de-
tected by t he presence of membrane-bound immunoglobulins by means 
of a fluorescein isothiocyanate- labeled JgG fraction of a goat ant ihuman 
Fab serum (Nordig, Tilburg, The Netherlands) [10]. 
Monoclonal Antibodies 
The monoclonal ant ibodies used in this study included OKT3, 
OKT4, OKT8 (Ortho Pharmaceuticals Corporation , Raritan New 
York) and ant i-HLA-DR antiserum (produced by Becton Dickinson, 
Facs. Systems, Sunnyvale, California) . The specificit ies of t hese mon-
oclonal ant ibodies have previously been described: OKT3 is reactive 
with a ll periphera l T cells and mature thymocytes (11], whereas OKT4 
a nd OKT8 define an inducer/ helper and cytotoxic/suppressor T-cell 
subset, respectively (12,13]. 
Anti -HLA-DR antiserum reacts with Ia- like antigens present on 
peripheral B cells, monocytes/macrophages, and activated T cells 
[14,15]. 
The percentages of cells reactive with these monoclonal antibodies 
were determined by means of an indirect immunofluorescence tech-
nique [16]. 
Ultrostru.ctu.ral Stu.dies 
Cell suspensions (2 X 106 cells) were fixed in a 2% cacodylate-
buffered glu ta raldehyde solution (pH 7.2) and embedded in Epon 812. 
U lt rathin sections were stained with uranyl acetate and lead citrate, 
a nd examined with the Siemens Elmiskop Ia. Morphometric analysis 
of t he lymphoid cells was perforined as described previously [17] . 
Briefly, from at least 75 lymphoid cells present on electron microscope 
photographs made of the cell suspensions, the nuclear perimeter and 
a rea were measured by means of a graphic tablet interfaced with a 
sma ll minicomputer (PDP 10/ 11). From these paramete rs t he nuclear 
contour index (NCI), which reflects the degree of nuclear indentation, 
perimeter . 
was calculated in t he following way: NCI = .j . Tins pa rameter 
area 
has a minimal value of 2Jn = 3.54 for a circular contour. In every 
patient t he mean and highest NCI values as well as the pe rcen t~e of 
CMC, which are morphologically defined as lymphoid cells with a NCI 
;;. 6.5 [ 17] were determined. 
S tatistical Analysis 
For statistical analysis Wilcoxon 's two-sample test was used. As a 
level of significance P < 0.05 was adapted. 
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RESULTS 
The total leukocyte and lymphocyte counts and t he percent-
ages of Sezary cells as observed in peripheral blood smears of 
the patients with SS and erythrodermic MF are shown in Table 
I. The percentages of lymphocytes, T and B cells, and T -cell 
subsets as defined by Fe receptors and monoclonal ant ibodies 
are shown in Table II. 
Three patients with SS (nos. 1- 3) and 1 patient with eryth-
rodermic MF (no. 12) showed highly raised leukocyte and 
lymphocyte counts . However, t he mean values in these groups 
were not significantly different from those of the benign groups. 
The mean percentage of lymphocytes in the patients with SS 
(53.9 ± 24.4) differed significantly from that in the pat ients 
with erythroderma on the basis of chronic dermatit is (18. 7 ± 
8.9; p < 0.003) and psoriasis (17.0 ± 11.4; p < 0.02). 
Rosette Assays 
The percentages of T cells, as defined by rosette formation 
with neuraminidase-treated sheep erythrocytes, were within 
normal limits in all pat ients studied, except for patients 3 and 
12, who showed decreased values (10 and 50%, respectively). 
The mean percentage of TJL cells in t he SS group was consid-
erably reduced and differed significantly from those in t he 3 
other groups, which showed normal values as compared to the 
healthy donor group. The mean percentages of T-y cells were 
decreased in t he pat ients with SS, chronic dermatitis, and 
psoriasis, but normal in t he pat ients with erythrodermic MF. 
The mean T-y value in the pat ients with SS (5.6 ± 2.8) was 
significantly lower than in the patients with erythrodermic MF 
(11.3 ± 1. 7; p < 0.02). 
Monoclonal Antibodies 
With respect to the distribution ofT-cell subsets, as defined 
by monoclonal ant ibodies, 7 of 8 patients with SS showed 
highly elevated percentages of cells reactive with OKT3 (pan-
T-cell phenotype) and OKT4 (helper/inducer T-cell pheno-
type ) antisera and strongly decreased percentages of OKT8+ 
cells (cytotoxic/suppressor T cell phenotype), resulting in sig-
nificantly increased T4/ T8 ratios. However, in 1 patient with 
strongly reduced lymphocyte counts (no. 6), completely normal 
percentages were observed. Patients with erythrodermic MF 
had normal OKT3 and OKT4, but significantly reduced OKT8 
values. The patients with atopic erythroderma tended to show 
increased OKT4 and decreased OKT8 values, resulting in 
slightly elevated T4/ T8 ratios. In t he other patients with ery-
throderma on the basis of chronic dermat itis and t hose with 
erythrodermic psoriasis, normal percentages of OKT3+, 
OKT4+, and OKT8+ cells were observed. The percentages of 
cells reactive with anti-HLA-DR antiserum were found within 
normal limits in most patients studied. 
Morphometric Analysis 
All 4 groups of patients with erythroderma showed elevated 
mean NCI values, decreased percentages of cells with a NCI < 
5.0, and increased percentages of CMC (lymphoid cells with 
NCI ;;. 6.5), compared with the healthy donor group (Table 
III) . The mean NCI value and the mean percentage of CMC 
were significant ly higher in t he pat ients with SS t han in the 
pat ients with an erythroderma on the basis of chronic derma-
titis or psoriasis. Moreover, lymphoid cells wit h a NCI ;;. 11.5 
were observed in 5 of 8 patients with SS but not in patients 
with benign inf1ammatory dermatoses. The results in t he SS 
group were apparently unrelated to the lymphocyte counts and 
the mode of t reatment. The highly increased mean NCI value 
and t he high percentage of CMC in 1 patient with leukemic 
MF (no. 12) were similar to those of t he patients with SS. The 
3 other patients wit h erythrodermic MF, however, showed only 
moderately increased mean NCI values and less than 20% CMC 
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TABLE I. Clinical characteristics of patients with S ezary 's syndrome (SS) and erythrodermic mycosis fun.goides (MF) 
Patient Sex Age Diagnosis Leukocytes" Lymphocytes" ezary ce lls• Lymph node Treatment at (% ) histo logy time of study 
1 M 50 ss 50.0 35.0 22 + Leukopheresis 
2 F 67 ss 28.0 23.0 63 + None 
3 M 56 ss 18.0 13.5 42 + Topical steroids 
4 M 70 ss 10.3 5.2 10 ND Topical steroids 
5 M 53 ss 6.8 1.6 33 + Chlorambucil, prednisone 
6 M 68 ss 6.6 0.8 30 + Chlorambuci l, prednisone 
7 F 67 ss 11.2 7.0 11 + Chlorambuc il , prednisone 
8 M 71 ss 8.5 4.4 0' + None 
9 M 65 MF 8.9 1.4 0 DL Topical steroids 
10 M 62 MF 7.5 1.1 0' DL Topical steroids, HN2 
11 F 64 MF 9.0 1.8 0 ' + Topical steroids, H N2 
12 M 69 MF 23 .5 18.8 ND + Topical steroids 
DL = dermopathic lymphadenopathy;+ refers to involvement; ND = not done. 
" Times 109/liter. 
• Percentage of peripheral blood lymphocytes. 
' In patients 8, 10, a nd 11 small numbers (<10%) of atypical lymphocytes were observed, but no hyperconvoluted Sezary cells. 
before therapy, and normal values after initial therapy (data 
not shown) . These results are similar to those observed in the 
patients with a benign form of erythroderma. 
DISCUSSION 
The results of the present study show that the most discrim-
inating parameters for the differentiation between SS and 
benign forms of erythroderma are (1) an increased percentage 
of lymphocytes, (2) an expanded OKT3+, OKT4+ population, 
and (3) a strongly increased mean NCI value, a percentage of 
CMC > 20%, and the presence of cells with a NCI ;:. 11.5 
(Table IV). The total leukocyte and lymphocyte counts as well 
as the percentages of B, T, TIL, and T-y cells had limited value 
for the early diagnosis of SS. 
The percentages of lymphocytes were 50% or more in 6 of 8 
patients with SS; 23 % or less in 17 of 20 patients with a benign 
form of erythroderma; and 30, 33, and 44%, respectively, in the 
3 other patients from the benign groups. The presence of more 
than 50% lymphocytes seems therefore highly indicative of the 
diagnosis of SS. The importance of a rising percentage of 
lymphocytes as criterion for the early diagnosis of SS has been 
mentioned previously [2). 
All but 1 patient with SS showed highly elevated OKT3 and 
OKT4, and decreased OKT8 values, and significantly increased 
OKT4/0KT8 ratios, which is in accordance with the results of 
previous studies [18- 21) . Patients with atopic erythroderma 
had slightly increased percentages of OKT4+ cells and de-
creased percentages of OKT8+ cells, compared with the healthy 
donor group, whereas patients with erythrodermic psoriasis 
showed completely normal values. Recent reports on the dis-
tribution of t hese T-cell subsets in atopic dermatit is [22] and 
psoriasis [21,23,24) have demonstrated similar results. The 
results of the present and other studies suggest that an OKT4/ 
OKT8 ratio of 10 or more can be used as a reliable criterion for 
the diagnosis of SS. 
Regarding the results of morphometric analysis, all patients 
with a benign form of erythroderma and 7 of 8 patients with 
SS were correctly classified when one or more of the following 
criteria were fulfilled: (1) a mean NCI value of 5.5 or more, (2) 
the presence of more than 20% CMC (lymphoid cells with a 
NCI ;;;. 6.5), or (3) the presence of cells with a NCI ;;;. 11.5, 
which to date have been observed only in patients with SS and 
MF, but not in patients with benign dermatoses [7]. Morpho-
metric analysis was repeated approximately 3 months after 
initial therapy in 1 patient with SS (no. 8), 2 patients with 
atopic erythroderma (nos . 14 and 15), and 3 patients with 
erythrodermic psoriasis (nos. 28, 29, and 31). The patient with 
early SS, who at first did not meet the aforementioned mor-
phometric criteria for SS, now showed a mean NCI value of 
5.83, 33.6% CMC, and a highest NCI value of 14.3. In the .5 
patients with atopic or psoriatic erythroderma, however, the 
mean NCI values (range: 4.09-4.60) and the percentages of 
CMC (range: 0-4.8%) had decreased to normal values. These 
results demonstrate that follow-up studies are essential for the 
correct diagnosis of SS in equivocal cases. 
The mean percentage of TIL cells was significantly lower in 
the patients with SS than in the patients with benign forms of 
erythroderma. However, the decrease in TIL cells in the SS 
group showed considerable variation. The patients with SS 
showed significantly reduced percentages of T-y cells, compared 
with the healthy donor group. However, strongly decreased T-y 
values were also observed in patients with atopic erythroderma 
and some patients with erythrodermic psoriasis. Together with 
the conflicting data on the distribution of TIL and T-y cells in 
recent literature [25,26), these observations indicate that the 
distribution of these T-cell subsets cannot be used as a major 
differential diagnostic criterion. 
The combined use of different investigations, as performed 
in the present study, adds to the diagnostic accuracy and seems 
worthwhile for the early diagnosis of SS. Patient no. 8 presented 
with a high percentage of lymphocytes and a significantly 
increased OKT4/0KT8 ratio, but at first did not meet the 
morphometric criteria for SS. Another patient, not ·included in 
the present study, presented in October 1982 with a noninfil-
trated erythroderma. The clinical and histologic findings were 
not diagnostic. Lymphadenopathy was not found. Total and 
differential white blood cell counts as well as the distribution 
of OKT3+, OKT4+, and OKT8+ cells were completely normal. 
However, because of the results of morphometric analysis 
(mean NCI value 6.0, 38% CMC, highest NCI value 13.6) the 
diagnosis of SS was suspected. In March 1983 this diagnosis 
was confirmed by histologic examination of an enlarged in -
guinal lymph node, and an OKT4/0KT8 ratio · of more 
than 10. 
In recent years the term erythrodermic CTCL for patients 
with SS has gained broad acceptance. However, this term does 
not permit differentiation between patients with SS and pa-
tients with MF who develop an erythroderma. The relationship 
between these two conditions, which is a matter of ongoing 
controversy, has recently been reviewed [27). In the present 
study 4 patients with erythrodermic MF were investigated. 
Apart from 1 patient who showed high leukocyte and lympho-
cyte counts, large numbers of CMC, and a significantly de-
creased proportion of OKT8+ cells, our patients with erythro-
dermic MF differed significantly from patients with SS because 
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TABLE II . Percentages of lymphocyte subpopulations in the peripheral blood of 32 patients with erythroderma 
Patient Diagnos is Leuk" Lymph EN Tl' T -y OKT3 OKT4 OKTS 
OKT4/ 0KT8 HLA-DR S lg 
ratio 
1 Sezary's syndrome 50.0 70 80 2 1 89 73 2 36.5 19 0 
2 Sezary's syndrome 28.0 83 71 36 7 94 95 3 31.7 5 4 
3 Seza ry's syndrome 18.0 75 10 87 85 1 85.0 7 11 
4 Sezary's syndrome 10.3 50 ND ND ND 88 82 3 27.3 8 ND 
5 Seza ry's syndrome 6.8 24 80 49 7 90 92 5 18.4 6 5 
6 Sezary's syndrome 6.6 14 73 32 8 69 54 20 2.7 10 12 
7 Sezary's syndrome 11.2 64 ND ND ND 94 93 5 18.6 5 ND 
8 Sezary's syndrome 8.5 51 76 17 5 96 93 3 31.0 2 4 
Mea n 17.4 53.9 65.0 27 .2 5.6 88.4 83.4 5.3 31.4 7.8 6.0 
SD 15.0 24.4 27.2 18.1 2.8 8.5 14.0 6.1 24.1 5.1 4.6 
9 Mycosis fun goides 8.9 15 70 46 9 60 54 4 13.5 24 30 
10 Mycosis fungoides 7.5 15 75 50 13 ND ND ND ND ND ND 
11 Mycosis fungoides 9.0 20 75 54 12 ND ND ND ND ND 13 
12 Mycosis fungoides 23.5 80 50 51 11 56 42 8 5.2 9 10 
Mea n 12.2 32.5 67.5 50.3 11.3 58.0 48.0 6.0 9.4 16.5 17.7 
SD 7.5 31.8 11 .9 3.3 1.7 2.8 8.5 2.8 5.9 10.6 10.8 
13 Atopic dermatitis 5.4 21 67 49 7 71 70 26 2.7 12 10 
14 Atopic dermatitis 3.6 21 72 56 6 81 68 11 6.2 ND 11 
15 Atopic dermatit is 10.9 12 73 35 7 ND ND ND ND ND 8 
16 Atopic dermatitis 8.9 14 76 43 11 85 69 20 3.5 16 7 
17 Atopic dermatitis 9.7 9 ND ND ND 67 55 11 5.0 8 ND 
18 Atopic dermat itis 7.6 21 74 53 9 65 52 24 2.2 11 13 
19 Atopic dermatitis 11.2 20 70 40 8 86 69 21 3.3 19 19 
20 Chronic dermatit is 7.8 16 80 51 10 ND ND ND ND ND 18 
21 Chron ic dermatitis 5.0 44 70 52 6 ND ND ND ND ND 15 
22 Chron ic dermatitis 9.5 23 74 47 11 76 52 24 2.2 14 14 
23 Chronic dermatit is 5.0 7 74 49 10 82 51 25 2.0 20 10 
24 Chronic dermatit is 8.6 16 67 48 10 68 49 25 2.0 13 16 
25 Chronic dermatitis 9.2 15 80 42 14 57 41 16 2.5 10 20 
26 Chronic de rmatit is 10.1 23 78 47 7 70 50 19 2.6 14 13 
Mean 8.0 18.7 73 .5 47.1 8.9 73.5 56.9 20.2 3.1 13.7 14.2 
SD 2.4 8.9 4.3 5.8 2.4 9.3 10.2 5.5 1.4 3.8 3.8 
27 Psoriasis 14 .8 3 76 47 11 ND ND ND ND ND 12 
28 Psoriasis 10.6 12 86 50 5 ND ND ND ND ND 15 
29 Psoriasis 7.6 23 70 40 13 67 45 25 1.8 19 8 
30 Psoriasis 9.3 14 85 50 7 72 68 23 3.0 ND 11 
31 Psoriasis 5.9 33 68 42 6 78 60 32 1.9 11 14 
32 Psoriasis 6.6 30 76 46 9 82 55 25 2.2 20 14 
Mean 9.1 19.2 76.8 45.8 8.5 74.8 57.0 26.3 2.2 16.7 12.3 
SD 3.3 11.5 7.4 4.1 3.1 6.6 9.6 3.9 0.5 4.9 2.6 
Hea lthy donors (n = 10) 
Mean 72.2 46.9 12.5 76.0 51.3 25.1 2.1 12.3 12.4 
SD 4.7 5.6 1.7 6.0 6.3 3.4 0.4 2.2 5.4 
Signifi cant differences (p values) 
SS vs Mycosis fungoides NS NS NS 0.03 O.Ql 0.04 0.05 NS NS NS NS 
SS vs Atopic/chronic derm NS 0.002 NS 0.02 0.05 0.002 0.001 0.001 0.001 O.Ql O.Ql 
:5>£ vs Psorias is NS 0.02 NS 0.04 NS 0.03 0.03 O.Ql 0.01 0.03 0.02 
LEUK = leukocytes 
LYMPH = lymp hocytes 
EN : percentage of tota l lymphocytes forming rosettes with neuraminidase-treated sheep erythrocytes 
T;c percentage ofT lymphocytes with Fc;.t receptor 
T -y: percentage ofT lymphocytes with Fe-y receptor 
Slg: percentage of lymphocytes bearing surface Ig 
ND: not done 
NS: not significant 
SD: standard deviation 
" Times 109/ liter. 
of n ormal to low lymphocyte counts, an a lmost norm a l distri-
bution of TJ.L and T-y cells, and t h e absence of highly elevated 
OKT3 and OKT4 values. M oreover , t h e moderately in c reased 
mean NCI values and percentages of CMC before t herapy, and 
t he n ormal values after initia l t he rapy con t rast with the per-
s istently hig h values in patients with SS. Whether t hese differ-
e nces between SS and erythrode rmic MF h ave a ny prognostic 
s ignifican ce remains to be establ is h ed . Until this question is 
settled it m ay be wise to avoid the term e rythrodermic CTCL 
a nd to con s ider t hese two diseases separately [27 ] . 
The morphometric measurements were performed in t he Depart-
ment of Cytophotometry and Morphometry (Head: Dr. C. J. Cornelisse) 
of the Depa rtment of Pathology, University Hospital, Leiden. 
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TABLE III. Morphometric analysis of peripheral blood lymphocytes of 32 patients with erythroderma 
Patient Mean NCI Highest NCI 
va lue va lue 
Sezary's syndrome (SS) 
1 6.4 10.7 
2 6.2 11.7 
3 5.5 11.3 
4 6.4 12.6 
5 6.3 12.7 
6 6.6 14.7 
7 5.8 11.6 
8 5.4 9.6 
Mean 6.1 11.9 
SD 0.4 1.5 
Mycosis fu.ngoides (MF) 
9 4.2 6.7 
10 4.8 9.2 
11 5.4 9.1 
12 5.8 10.7 
Mean 5.1 8.9 
SD 0.7 1.7 
Atopic/chronic dermatitis (AD/CD) 
13 4.5 7.8 
14 4.8 8.8 
15 5.4 10.3 
16 5.1 11.1 
17 4.4 7.6 
18 4.5 7.7 
19 5.0 7.7 
20 4.4 6.7 
21 ND ND 
22 4.4 8.9 
23 4.7 8.2 
24 5.0 8.4 
25 4.7 8.9 
26 4.2 6.0 
Mean 4.7 8.3 
SD 0.3 1.4 
Psoriasis 
27 5.2 9.4 
28 5.3 10.6 
29 4.5 7.3 
30 4.8 7.8 
31 5.1 9.3 
32 4.9 8.6 
Mean 5.0 8.8 
SD 0.3 1.2 
Healthy donors (n = 5) 
Mean 4.3 7.6 
SD 0.1 0.9 
Significant differences (p values) 
ss VS MF 0.02 0.02 
ss VS AD/CD 0.0002 0.0004 
SS vs Psoriasis 0.002 0.003 
NCI = nuclear contour index; ND = not done; NS = not significant 
TABLE IV. Diagnostic criteria for Sezary's syndrome in the peripheral 
blood 
Lymphocytosis ~ 50% 
OKT4/0KT8 ratio > 10 
Mean NCI ~ 5.5 
CMC> 20% 
Cells with NCI ~ 11.5 
Sezary's 
syndrome 
























"Erythroderma on the basis of chronic dermatitis, atopic dermatitis, 
or psoriasis . 
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Subsets of Epidermal Langerhans Cells as Defined by Lectin Binding 
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In this study we characterize the cell surface glyco-
conjugate moieties of strain 2 guinea pig epidermal Lan-
gerhans cells (LC) in single cell suspension by using a 
battery of 17 fluorescent lectins. All LC displayed bind-
ing sites for concanavalin A, succinylated concanavalin 
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Abbreviations: 
anti-l a.2,4: stra in 13 ant i-strain 2 serum 
EC: epidermal cell(s) 
FITC: fluorescein -isothiocyanate 
FITC-SpA: F!TC-labeled staphylococcal protein A 
HRP: horseradish peroxidase 
Ia: immune response-associated (antigens) 
LC: Langerhans cell(s) 
Lectins: 
Con A: concanavalin A 
A, Lens culinaris agglutinin, Pisum sativum agglutinin, 
wheat germ agglutinin, succiny lated wheat germ agglu-
tinin, Griffonia simplicifolia agglutinin I, Ricinus com-
munis agglutinin I, Phaseolus vulgaris E agglutinin, and 
Phaseolus vulgaris L agglutinin, but failed to bind So-
DBA: Dolichos biflorus agglut ini n 
GS I-B4: Gnffonia simplicifolia. l -B., isolectin 
GSL I: Griffonia simplicifolia agglu t inin I 
HPA: H elix pomatia agglut inin 
LCA: Lens culina.ris agglu t inin 
PHA-E: Phaseolus vu./garis E agglut inin 
PHA-L: Phaseolus vulgaris L agglut inin 
PNA: peanut agglut inin 
PSA: Piswn sa.tivu.m agglut inin 
RCA I: Ricinus communis agglut inin I 
SBA: soybean agglutinin 
SJA: Sophorica japonica agglutinin 
succ. Con A: Succ inylated Con A 
succ. WGA: succinylated WGA 
UEA 1: Ulex eu.ropaeu.s agglu tinin I 
WGA: wheat germ agglut inin 
PBS-azide: phosphate-bu ffered saline supplemented wit h 0.02% 
sodium azide 
TRITC: tetramethylrhodamine-isothiocyanate 
